The ILLUMINATE-101 Study is a phase 2 clinical research study evaluating the safety and effectiveness of an investigational medication designed to reduce or eliminate the negative immune response to gluten in adults with celiac disease.
Continue ReadingHalloween is just around the corner, and this year the Celiac Disease Foundation is proud to partner again with our friends at Food Allergy Research & Education (FARE) to promote the Teal Pumpkin Project, which aims to make this holiday safer for everyone affected by celiac disease, food allergies, intolerances, and other conditions.
Continue ReadingMany conventional brands actually have a hidden source of gluten in the ingredients list!
Continue ReadingWhat if there was a way to help your immune system become more tolerant of gluten? That’s the potential of VTP-1000, an investigational immunotherapy being studied in the AVALON celiac disease clinical trial.
Continue ReadingOn May 20 the Disease Foundation hosted its third annual award reception at Digestive Disease Week in Washington, D.C. From prestigious global research prizes to inaugural student and policy leadership awards, the event spotlighted the extraordinary contributions of individuals dedicated to improving the lives of those affected by celiac disease.
Continue ReadingThe Celiac Disease Foundation is proud to share that for the second year in a row, access to funding for celiac disease research is being made available through the U.S. DOD Congressionally Directed Medical Research Programs (DOD-CDMRP)Peer Review Medical Research Program.
Continue ReadingA new study published in the journal Gastro Hep Advances finds that a considerable proportion of Black patients with biopsy-confirmed celiac disease had negative diagnostic blood tests. Traditionally perceived as predominantly affecting non-Hispanic White individuals, this study underscores the importance of bridging existing research gaps to better serve underrepresented populations.
Continue ReadingUsing data from the Foundation’s iCureCeliac® Patient Registry, a new observational study helps explain the relationship between persistent celiac disease symptoms, gluten-free diet adherence, mental health, and quality of life.
Continue ReadingThe Celiac Disease Foundation, a global leader in celiac disease patient advocacy, today announces its new relationship with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to provide resources for celiac disease patients and all consumers concerned about potential gluten in the company’s medications.
Continue ReadingThe Celiac Disease Foundation and Celiac Cruise are pleased to announce an innovative partnership to offer safe and delicious gluten-free travel experiences, provide educational opportunities, and foster philanthropy within the celiac disease community.
Continue ReadingDear Celiac Disease Foundation Community, For more than three decades, the Celiac Disease Foundation has been dedicated to improving the lives of those affected by celiac disease through research, advocacy, and education. What began as a grassroots effort has grown into a global organization, leading the charge in accelerating diagnosis,...